Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) will report second quarter 2026 financial results after market close on July 29, 2026. Management will host a webcasted conference call at 1:30 p.m. PT / 4:30 p.m. ET.
The live and archived audio will be accessible via the company’s Investors website.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings date: ADPT -3.39% in the Jul 10 session
In the Jul 10 session, ADPT declined 3.39%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.5% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Earnings date notice | Neutral | -3.1% | Announced timing of 1Q26 earnings release and post-close conference call. |
| Jan 22 | Earnings date notice | Neutral | -2.7% | Set date for 4Q25 and full-year 2025 results and investor call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings-date notices for ADPT were followed by modest share price declines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
